Terms: = Prostate cancer AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546 AND Staging
4 results:
1. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
Haran C; McBean R; Parsons R; Wong D
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
[TBL] [Abstract] [Full Text] [Related]
2. Interreader agreement of PI-RADS v. 2 in assessing prostate cancer with multiparametric MRI: A study using whole-mount histology as the standard of reference.
Girometti R; Giannarini G; Greco F; Isola M; Cereser L; Como G; Sioletic S; Pizzolitto S; Crestani A; Ficarra V; Zuiani C
J Magn Reson Imaging; 2019 Feb; 49(2):546-555. PubMed ID: 30187600
[TBL] [Abstract] [Full Text] [Related]
3. Predictors of adverse pathologic features after radical prostatectomy in low-risk prostate cancer.
Park JW; Koh DH; Jang WS; Cho KS; Ham WS; Rha KH; Hong SJ; Choi YD
BMC Cancer; 2018 May; 18(1):545. PubMed ID: 29743042
[TBL] [Abstract] [Full Text] [Related]
4. Stereotactic body re-irradiation therapy for locally recurrent prostate cancer after external-beam radiation therapy: Initial report.
Janoray G; Reynaud-Bougnoux A; Ruffier-Loubière A; Bernadou G; Pointreau Y; Calais G
Cancer Radiother; 2016 Jun; 20(4):275-81. PubMed ID: 27342944
[TBL] [Abstract] [Full Text] [Related]
